Показ 1 - 5 результатів із 5 для пошуку 'Seyed Reza Mousavi (13223324)', час виконання запиту: 0.01сек. Уточнити результати
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. за авторством Seyed Reza Mousavi (13223324)

    Опубліковано 2025
    Додати у Вибране
    Збережено в:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. за авторством Seyed Reza Mousavi (13223324)

    Опубліковано 2025
    Додати у Вибране
    Збережено в:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. за авторством Seyed Reza Mousavi (13223324)

    Опубліковано 2025
    Додати у Вибране
    Збережено в:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. за авторством Seyed Reza Mousavi (13223324)

    Опубліковано 2025
    Додати у Вибране
    Збережено в:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. за авторством Seyed Reza Mousavi (13223324)

    Опубліковано 2025
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: